National and Kapodistrian University of Athens
Μελέτη της σύστασης και της λειτουργίας της λιποπρωτεΐνης υψηλής πυκνότητας (HDL) σε παθολογικές καταστάσεις, καθώς και της ενίσχυσης των αθηροπροστατευτικών λειτουργιών της HDL με μικρά μόρια
Abstract
dc:descriptionHigh-density lipoprotein (HDL) is a macromolecular complex of lipids and proteins that protects from atherosclerosis and cardiovascular disease (CVD) by exerting a series of functions, such as ability to remove excess cholesterol from macrophages in the arterial wall, antioxidant capacity, etc. Apolipoprotein A-I (apoA-I), the main protein of HDL, as well as other protein and lipid components of HDL, are involved in its atheroprotective functions. Mutations in protein components of HDL, as well as chronic inflammatory diseases, such as Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis (RA), lead to impairment of HDL composition and atheroprotective properties and an increased risk for atherosclerosis and CVD. In the first part of this study, the impact of biological treatments on the HDL composition and functions in patients with SLE and RA was evaluated. Firstly, it was investigated the impact of treatment with belimumab in patients with SLE. Belimumab is a monoclonal antibody against B-cell activating factor (BAFF), implicated in disease progression and associated with subclinical atherosclerosis. The analyses showed that belimumab treatment may improve the HDL atheroprotective properties and modify the HDL lipidomic signature in SLE patients, thus potentially mitigating atherosclerosis development. Additionally, the impact of treatments with biological agents (anti-TNF-α, abatacept) on the HDL function and composition in patients with RA was evaluated. The analyses showed no significant changes in patients’ HDL atheroprotective properties following these specific treatments. In the second part of this study, a screening of marketed drug libraries (956 compounds) was performed to identify new compounds that can enhance or improve HDL atheroprotective properties. Specifically, the ability of compounds to increase the activity of the antioxidant enzyme paraoxonase 1 (PON1), which is associated with HDL and is involved in its atheroprotective functions, was examined. Reductions in PON1 activity have been observed in patients with RA and have been associated with an increased risk of CVD. Screening analyses resulted in the identification of the drug dantrolene as a PON1 activator, which was validated by enzymatic kinetic studies using recombinant human PON1. These findings indicate that the use of small molecules to enhance the HDL-associated PON1 activity is a feasible approach that may lead to new therapeutic approaches for CVD. Finally, it was examined whether compounds identified, by a drug library screening, to ameliorate the defective structure of apoA-I[L178P] can also improve the apoA-I[L178P] function. ApoA-I[L178P] is a mutant form of apoA-I displaying major defects in its structural integrity and atheroprotective function underlying the increased CVD risk observed in carriers of the mutation. The analyses showed that the drug bexarotene leads to the restoration of apoA-I[L178P] atheroprotective function indicating that small molecules can correct the defective structure and function of apoA-I leading to new therapeutic approaches for apoA-I-related dyslipidemias and increased cardiovascular risk.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2024
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Dedemadi, Anastasia-Georgia
- Δεδεμάδη, Αναστασία-Γεωργία
Subjects
dc:subject × 30- Ρευματοειδής αρθρίτιδα
- Συστηματικός ερυθηματώδης λύκος
- Βιολογικοί παράγοντες
- Λιποπρωτείνη υψηλής πυκνότητας (HDL)
- Αθηροπροστασία
- Αθηροσκλήρωση
- Λιπιδομικό προφίλ
- Παραοξονάση 1 (PON1)
- Απολιποπρωτείνη Α-Ι (αποΑ-Ι)
- Βιβλιοθήκες φαρμάκων
- Rheumatoid arthritis
- Systemic lupus erythematosus
- Biologic agents
- High-density lipoprotein (HDL)
- Atheroprotection
- Atherosclerosis
- Lipidomic profile
- Paraoxonase 1 (PON1)
- Apolipoprotein A-I (apoA-I)
- Drug libraries
- Χημεία
- Φυσικές Επιστήμες
- Χημεία, άλλοι τομείς
- Βιολογία
- Βιοχημεία και Μοριακή βιολογία
- Chemical Sciences
- Natural Sciences
- Chemistry, miscellaneous
- Biological Sciences
- Biochemistry and Molecular Biology
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/57706